Trending...
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- The AI CEO™ Launches Next-Gen Sales Assistant for Equipment Finance Professionals
GROSSE POINTE, Mich. - Michimich -- SciTech Development announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square. Earle Holsapple, President will be presenting SciTech's innovative ST-001 nanoFenretinide technology at Biotech Showcase as follows:
Date: Monday, January 13, 2020
Time: 11:15 AM (PST)
Room: Franciscan B
Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA
Qualified investors can register to attend Biotech Showcase for free.
ST-001 nanoFenretinide is a small-molecule cancer drug comprised of nanoparticle sized fenretinide in a patented combination with carefully selected phospholipids. SciTech's product pipeline includes nanoFenretinide formulations for the treatment for several cancer indications. The FDA has granted Orphan Drug Status for ST-001 nanoFenretinide in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
More on Michimich.com
About SciTech Development
SciTech Development, LLC is a clinical stage oncology drug company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. Information regarding SciTech's nano formulation technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling (313) 938-5517 or at https://www.scitechdevelopment.com/ . You can follow SciTech Development on Twitter at @SciTechUSA
About Biotech Showcase
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
More on Michimich.com
Forward-Looking Information
This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.
Date: Monday, January 13, 2020
Time: 11:15 AM (PST)
Room: Franciscan B
Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA
Qualified investors can register to attend Biotech Showcase for free.
ST-001 nanoFenretinide is a small-molecule cancer drug comprised of nanoparticle sized fenretinide in a patented combination with carefully selected phospholipids. SciTech's product pipeline includes nanoFenretinide formulations for the treatment for several cancer indications. The FDA has granted Orphan Drug Status for ST-001 nanoFenretinide in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
More on Michimich.com
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Rocket Companies Completes Acquisition of Redfin
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
About SciTech Development
SciTech Development, LLC is a clinical stage oncology drug company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. Information regarding SciTech's nano formulation technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling (313) 938-5517 or at https://www.scitechdevelopment.com/ . You can follow SciTech Development on Twitter at @SciTechUSA
About Biotech Showcase
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
More on Michimich.com
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- NEW CHILDREN'S BOOK RELEASE: "Mommy, Where Is My Daddy?" by Tracy L. Gray
- UNIVERSAL MUSIC GROUP AND THE UCLA HERB ALPERT SCHOOL OF MUSIC ESTABLISH THE BERRY GORDY MUSIC INDUSTRY SCHOLARSHIP TO HONOR THE LEGACY OF A MUSIC PIONEER
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
Forward-Looking Information
This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.
Contact
Earle Holsapple
Tel: +1-313-938-5517 Email: eth@scitechdevelopment.com
***@scitechdevelopment.com
Earle Holsapple
Tel: +1-313-938-5517 Email: eth@scitechdevelopment.com
***@scitechdevelopment.com
Source: SciTech Development, LLC
0 Comments
Latest on Michimich.com
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- PrideStaff Detroit (West) Named One of Detroit's Top Staffing Agencies for Second Year by ThreeBestRated®
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
- Suzanne Harp named Managing Director in Texas, USA
- $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
- The AI CEO™ Launches Next-Gen Sales Assistant for Equipment Finance Professionals
- PGA Tour's Rocket Mortgage Classic: Detroit Readies for a Championship Clash
- An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
- Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
- New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
- Alpha Modus Files 7th IP Action Against Rackspace Following $3M CEO Investment and Strategic Partnership Expansion